Enanta Pharmaceuticals Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks.

7 equities research analysts have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their ENTA stock forecasts range from $44.00 to $103.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $74.14 in the next twelve months. This suggests a possible upside of 64.7% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $74.78 on January 1st, 2022. Since then, ENTA stock has decreased by 39.8% and is now trading at $45.01.
View the best growth stocks for 2022 here.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its earnings results on Monday, May, 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.20. The biotechnology company had revenue of $18.72 million for the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 28.80% and a negative net margin of 122.68%. During the same period last year, the company posted ($1.09) EPS.
View Enanta Pharmaceuticals' earnings history.

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Enanta Pharmaceuticals include Galapagos (GLPG), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Karuna Therapeutics (KRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), CureVac (CVAC), Indivior (INVVY), Pacira BioSciences (PCRX) and Insmed (INSM).
View all of ENTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.13%), Vanguard Group Inc. (7.67%), Farallon Capital Management LLC (7.48%), State Street Corp (6.32%), RA Capital Management L.P. (4.66%) and Northern Trust Corp (4.48%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Granahan Investment Management LLC, Renaissance Technologies LLC, Northern Trust Corp, Acadian Asset Management LLC, Candriam Luxembourg S.C.A., Vanguard Group Inc., and Citigroup Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last two years include Bruce L A Carter, Jay R Luly, Nathalie Adda, and Paul J Mellett.
View insider buying and selling activity for Enanta Pharmaceuticals or view top insider-selling stocks.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Deep Track Capital LP, State Street Corp, Fairmount Funds Management LLC, Invesco Ltd., BlackRock Inc., Walleye Capital LLC, and Walleye Capital LLC.
View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $45.01.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $932.29 million and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($5.52) on an earnings per share basis.

Enanta Pharmaceuticals employs 155 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for Enanta Pharmaceuticals is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.